We added a position in Kyowa Kirin (TSE:4151, Financial). The pharmaceuticals and biochemicals company is a transformational product story, driven by the regulatory approval of three antibodies. We believe that market participants are underestimating the growth that will be derived from the company’s innovation, providing us with a compelling entry point.
From the T. Rowe Price Japan Fund (Trades, Portfolio)'s 2019 annual shareholder letter.
Also check out:
